Emergent’s Statement on Over-the-Counter Access, Availability and Pricing of NARCAN® Naloxone HCl Nasal Spray 4 mg
On the heels of last month’s FDA approval of NARCAN® Naloxone HCl Nasal Spray 4 mg for the over-the-counter (OTC) use of opioid overdose emergency, Emergent is committed to increasing awareness of...
Emergent BioSolution’s Statement on the Status of its Credit Facility and the Sale of its Travel Health Business
GAITHERSBURG, Md., April 17, 2023 – Emergent BioSolutions (NYSE: EBS) previously announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a...
Emergent BioSolutions Sponsors Manufacturing Day 2022, Declaring Manufacturing Matters & Inspiring New Generation of Talent
NAM and MI Celebrate #MFGDay2022 to Give Students Inside Look at Modern Manufacturing, Emergent Leaders Tour Lansing, Michigan Manufacturing Site with Local High School Students Washington, D.C. –...
Emergent BioSolutions Statement on the Status of its Camden Manufacturing Facility
GAITHERSBURG, Md., August 12, 2022 – Emergent (NYSE: EBS) received a communication from the FDA on August 10, 2022. That communication included the issuance of a warning letter. We share the...
Emergent’s Response to U.S. Senator Tammy Baldwin and Congressional Leaders Regarding Access to Naloxone
In response to a letter led by Senator Tammy Baldwin requesting manufacturers submit an FDA application to make naloxone available over-the-counter (OTC), Emergent expressed its commitment to...
Emergent Response to New Congressional Report
There is nothing new. This report details the same information we have transparently given to regulators and the media over the past two years. Emergent has been open and forthcoming with the FDA,...
Emergent BioSolutions Statement on the Federal Court of Appeals’ Ruling on NARCAN® Nasal Spray Patents
GAITHERSBURG, Md., February 10, 2022 – Today, the Court of Appeals for the Federal Circuit (CAFC) issued a decision affirming the District Court’s decision in our patent litigation case with...
Emergent BioSolutions Statement on Generic Version of NARCAN® Nasal Spray
Based on publicly available information, it appears that Teva Pharmaceutical Industries Ltd. has launched a generic naloxone nasal spray, prior to resolution of the related pending patent...
Emergent Releases Inaugural ESG Report
GAITHERSBURG, M.D. – Emergent BioSolutions (NYSE: EBS) today released the inaugural edition of its environmental, social and governance (ESG) report. The report documents Emergent’s approach to...
Emergent and HHS Agree to End CIADM Arrangement
Emergent BioSolutions (NYSE: EBS) and the U.S. Department of Health and Human Services (HHS) have mutually agreed to Emergent’s proposal to end its involvement in the Centers for Innovation in...
Emergent BioSolutions Sponsoring MFG Day 2021, Inspiring New Generation of Manufacturing Talent
Advancing Mission of Nationwide “Creators Wanted” Workforce Campaign, MFG Day Highlights Modern Manufacturing Careers for Students, Parents, Teachers and Leaders Washington, D.C. – The...
Emergent BioSolutions Takes a Stand Against the Opioid Epidemic on International Overdose Awareness Day
Today, Emergent BioSolutions recognizes International Overdose Awareness Day, as part of Overdose Awareness Week, and the dedicated efforts of lifestyle influencer Dani Schaffer to address the...